This post-market study is being conducted to document comparative safety, clinical effectiveness, and cost-effectiveness of the addition of HF10™ therapy to CMM compared with CMM alone in subjects with chronic, intractable, neuropathic lower limb pain due to diabetic neuropathy (Painful Diabetic Neuropathy or PDN). This study is a multi-center, prospective, randomized comparison of the two treatments.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
430
Senza 10kHz Spinal Cord Stimulation
Conventional Medical Management
Coastal Orthopedics
Bradenton, Florida, United States
Georgia Pain Care
Stockbridge, Georgia, United States
Duke University Medical Center
Durham, North Carolina, United States
Advanced Pain Management
Greenfield, Wisconsin, United States
Composite of Safety and Effectiveness
Difference between treatment groups in responder rates in subjects without a clinically meaningful neurological deficit compared with baseline. Responder is defined as a subject who has at least 50% reduction in lower limb pain from Baseline as measured by a 10 cm Visual Analog Scale (VAS).
Time frame: 3 months
Pain Scores of 3 or Less
Difference between the treatment groups in proportion of subjects with a lower limb pain VAS score ≤ 3 cm.
Time frame: 3 months
Crossover Rates
Difference between the treatment groups in crossover rates. Subjects who meet pre-specified criteria may elect to crossover to the other treatment arm at 6-month follow-up.
Time frame: 6 months
Responder Rates
Difference between the treatment groups in responder rates. Responder is defined as a subject who has at least 50% reduction in lower limb pain from Baseline as measured by a 10 cm Visual Analog Scale (VAS).
Time frame: 6 months
Remitter Rates
Difference between the treatment groups in the proportion of remitters (remission is defined as having a lower limb pain VAS score of ≤ 3.0 cm for at least 6 months).
Time frame: 6 months
Neurological Assessment
Difference between the treatment groups in the proportion of subjects with overall improvement from baseline in neurological assessment (motor, sensory, reflex).
Time frame: 3 months
Neurological Assessment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Difference between the treatment groups in the proportion of subjects with overall improvement from baseline in neurological assessment (motor, sensory, reflex).
Time frame: 6 months
Health-related Quality of Life
Difference between the treatment groups in changes in health-related quality of life as assessed by the EuroQol Five Dimensions questionnaire (EQ-5D-5L).
Time frame: 6 months
Hemoglobin A1c
Difference between the treatment groups in the average percentage change from baseline in HbA1c levels.
Time frame: 6 months